UA62784, a novel inhibitor of centromere protein E kinesin-like protein

Meredith C. Henderson, Yeng Jeng Y Shaw, Hong Wang, Haiyong Han, Laurence Hurley, Gary Flynn, Robert T Dorr, Daniel D. Von Hoff

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Pancreatic carcinoma is the fourth leading cause of death from cancer. Novel targets and therapeutic options are needed to aid in the treatment of pancreatic cancer. The compound UA62784 is a novel fluorenone with inhibitory activity against the centromere protein E (CENP-E) kinesin-like protein. UA62784 was isolated due to its selectivity in isogenic pancreatic carcinoma cell lines with a deletion of the DPC4 gene. UA62784 causes mitotic arrest by inhibiting chromosome congression at the metaphase plate likely through inhibition of the microtubule-associated ATPase activity of CENP-E. Furthermore, CENP-E binding to kinetochores duringmitosis is not affected by UA62784, suggesting that the target lies within the motor domain of CENP-E. UA62784 is a novel specific inhibitor of CENP-E and its activity suggests a potential role for antimitotic drugs in treating pancreatic carcinomas.

Original languageEnglish (US)
Pages (from-to)36-44
Number of pages9
JournalMolecular Cancer Therapeutics
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Kinesin
Proteins
Antimitotic Agents
Kinetochores
Gene Deletion
Metaphase
Pancreatic Neoplasms
Protein Binding
Microtubules
Adenosine Triphosphatases
Cause of Death
Chromosomes
centromere protein E
UA 62784
Cell Line
Pancreatic Carcinoma
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Henderson, M. C., Shaw, Y. J. Y., Wang, H., Han, H., Hurley, L., Flynn, G., ... Von Hoff, D. D. (2009). UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Molecular Cancer Therapeutics, 8(1), 36-44. https://doi.org/10.1158/1535-7163.MCT-08-0789

UA62784, a novel inhibitor of centromere protein E kinesin-like protein. / Henderson, Meredith C.; Shaw, Yeng Jeng Y; Wang, Hong; Han, Haiyong; Hurley, Laurence; Flynn, Gary; Dorr, Robert T; Von Hoff, Daniel D.

In: Molecular Cancer Therapeutics, Vol. 8, No. 1, 01.01.2009, p. 36-44.

Research output: Contribution to journalArticle

Henderson, Meredith C. ; Shaw, Yeng Jeng Y ; Wang, Hong ; Han, Haiyong ; Hurley, Laurence ; Flynn, Gary ; Dorr, Robert T ; Von Hoff, Daniel D. / UA62784, a novel inhibitor of centromere protein E kinesin-like protein. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 1. pp. 36-44.
@article{fcf8003ab34149ac969e1c9c40b62833,
title = "UA62784, a novel inhibitor of centromere protein E kinesin-like protein",
abstract = "Pancreatic carcinoma is the fourth leading cause of death from cancer. Novel targets and therapeutic options are needed to aid in the treatment of pancreatic cancer. The compound UA62784 is a novel fluorenone with inhibitory activity against the centromere protein E (CENP-E) kinesin-like protein. UA62784 was isolated due to its selectivity in isogenic pancreatic carcinoma cell lines with a deletion of the DPC4 gene. UA62784 causes mitotic arrest by inhibiting chromosome congression at the metaphase plate likely through inhibition of the microtubule-associated ATPase activity of CENP-E. Furthermore, CENP-E binding to kinetochores duringmitosis is not affected by UA62784, suggesting that the target lies within the motor domain of CENP-E. UA62784 is a novel specific inhibitor of CENP-E and its activity suggests a potential role for antimitotic drugs in treating pancreatic carcinomas.",
author = "Henderson, {Meredith C.} and Shaw, {Yeng Jeng Y} and Hong Wang and Haiyong Han and Laurence Hurley and Gary Flynn and Dorr, {Robert T} and {Von Hoff}, {Daniel D.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-08-0789",
language = "English (US)",
volume = "8",
pages = "36--44",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - UA62784, a novel inhibitor of centromere protein E kinesin-like protein

AU - Henderson, Meredith C.

AU - Shaw, Yeng Jeng Y

AU - Wang, Hong

AU - Han, Haiyong

AU - Hurley, Laurence

AU - Flynn, Gary

AU - Dorr, Robert T

AU - Von Hoff, Daniel D.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Pancreatic carcinoma is the fourth leading cause of death from cancer. Novel targets and therapeutic options are needed to aid in the treatment of pancreatic cancer. The compound UA62784 is a novel fluorenone with inhibitory activity against the centromere protein E (CENP-E) kinesin-like protein. UA62784 was isolated due to its selectivity in isogenic pancreatic carcinoma cell lines with a deletion of the DPC4 gene. UA62784 causes mitotic arrest by inhibiting chromosome congression at the metaphase plate likely through inhibition of the microtubule-associated ATPase activity of CENP-E. Furthermore, CENP-E binding to kinetochores duringmitosis is not affected by UA62784, suggesting that the target lies within the motor domain of CENP-E. UA62784 is a novel specific inhibitor of CENP-E and its activity suggests a potential role for antimitotic drugs in treating pancreatic carcinomas.

AB - Pancreatic carcinoma is the fourth leading cause of death from cancer. Novel targets and therapeutic options are needed to aid in the treatment of pancreatic cancer. The compound UA62784 is a novel fluorenone with inhibitory activity against the centromere protein E (CENP-E) kinesin-like protein. UA62784 was isolated due to its selectivity in isogenic pancreatic carcinoma cell lines with a deletion of the DPC4 gene. UA62784 causes mitotic arrest by inhibiting chromosome congression at the metaphase plate likely through inhibition of the microtubule-associated ATPase activity of CENP-E. Furthermore, CENP-E binding to kinetochores duringmitosis is not affected by UA62784, suggesting that the target lies within the motor domain of CENP-E. UA62784 is a novel specific inhibitor of CENP-E and its activity suggests a potential role for antimitotic drugs in treating pancreatic carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=58149483360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149483360&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0789

DO - 10.1158/1535-7163.MCT-08-0789

M3 - Article

C2 - 19139111

AN - SCOPUS:58149483360

VL - 8

SP - 36

EP - 44

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -